In hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- and triple-negative breast cancer (TNBC) subtypes, young patients are more likely to reach pCR, while there is no such difference in other subtypes of BC. Here, ERBB2 is linked to triple-negative breast carcinoma.